Biomay's grass pollen allergy vaccine shows efficacy in phase IIa trial

15-06-2012: Biomay AG announced promising results from a First-in-Man Phase IIa trial with its allergy vaccine BM32. The vaccine significantly reduced allergy-related nasal symptoms in a study group of 70 patients suffering from grass pollen allergy. The environmental challenge study also showed that BM32 significantly reduced skin reactivity to grass pollen as demonstrated by skin prick testing. The treatment was shown to be safe and was generally well tolerated, despite the fact that a full dose of the vaccine was given from the first day of treatment. All in all, patients were given three doses of BM32 or a placebo by subcutaneous injections over a period of two months. This dosing regimen offers a dramatic improvement over conventional immunotherapy, which requires multiple injections.

Dr. Rainer Henning, CEO of Biomay AG, commented: "We are very encouraged by these exciting data. They validate our scientific hypothesis that Biomay´s proprietary recombinant peptide carrier technology can form the basis of vaccines that induce the production of protective antibodies against allergenic proteins contained in grass pollen, which are the root cause of the disease. At the same time, this technology reduces the risk of side effects and the need for multiple injections."